Fulltext present in this item

Thumbnail
Fulltext: 69675.pdf
Format: PDF
Embargo: until further notice
Title: Cholesterol in end-stage renal disease: the good, the bad or the ugly?
Author(s): Diepeveen, S.H.A. ; Wetzels, J.F.M. ; Bilo, H.J.; Tits, L.J.H. van ; Stalenhoef, A.F.H.
Publication year: 2008
Source: Netherlands Journal of Medicine, vol. 66, iss. 2, (2008), pp. 53-61
ISSN: 0300-2977
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/69675   https://hdl.handle.net/2066/69675

Display more details
Subject: IGMD 5: Health aging / healthy living
IGMD 7: Iron metabolism
IGMD 9: Renal disorder
NCEBP 14: Cardiovascular diseases
UMCN 2.2: Vascular medicine and diabetes
UMCN 5.1: Genetic defects of metabolism
UMCN 5.4: Renal disorders
Organization: Internal Medicine
Nephrology
Journal title:
Netherlands Journal of Medicine
Volume: vol. 66
Issue: iss. 2
Page start: p. 53
Page end: p. 61
Abstract:
The incidence of cardiovascular disease is markedly increased in patients with end-stage renal disease (ESRD). High serum cholesterol is widely recognised as a cardiovascular risk factor in the general population. However, in patients with ESRD high concentrations of cholesterol are associated with a better survival. This reverse epidemiology is, amongst others, caused by confounding due to malnutrition and chronic inflammation. In this population, treatment with statins to lower the serum cholesterol remains a matter of debate. In ESRD, LDL cholesterol is modified by increased oxidative stress. These altered LDL particles play a pivotal role in the development of atherosclerosis. Treatment with the antioxidant vitamin E has not equivocally been shown to be beneficial in this population. This review tries to put data from literature on dyslipidaemia and oxidative stress in ESRD in perspective.

This item appears in the following Collection(s)

Browse

Statistics